Vancouver, British Columbia, Canada, September 23, 2025 – TheNewswire – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health”), plans to establish its Health AI Centre operations in Hong Kong.
“Mindleap Health is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative Medicine (“CAM”) market and key to this platform will be access to health datasets in Asia and AI models developed by researchers in Asia”, said Robert Nygren, Executive Chair of PanGenomic Health and President of its wholly-owned subsidiary Mindleap Health. “With the support of a strategic advisory firm based in Hong Kong, we will set up a Health AI Centre in the fourth quarter of this year that will include development, research and marketing resources to advance our Mindleap RWE platform for CAM.”
The Mindleap RWE platform will collect and analyze health data from a broad range of traditional and non-traditional sources, including clinical research studies from Western and non-Western countries, long-documented history of human use and evidence of modern use. The goal of the Mindleap RWE platform will be to become a trusted source of information about non-pharmaceutical health solutions.
Mindleap Health selected Hong Kong to be the location of its Health AI Centre given Hong Kong’s diverse patient populations, its strong government support for AI-driven healthcare and its status as a hub for medical technology innovation in the Asia Pacific region. Hong Kong also provides access to a range of multi-lingual university researchers focused on data science, artificial intelligence, and interdisciplinary collaboration.
About Mindleap Health
Mindleap Health is a provider of holistic health and wellness information. To learn more about Mindleap Health’s products and services: www.mindleap.com or email: support@mindleap.com
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform
to deliver personalized, evidence-based information about natural treatments. The Company’s
initial focus is to support mental health. Registered as a British Columbia benefit company,
PanGenomic Health’s mission is to promote and improve the health and wellness of people and
society by providing a technology platform that identifies plant-based solutions tailored to the
health profile of each individual.
For more information, please contact:
Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 366 6277
connect@fairfaxpartners.ca
This news release includes certain statements that may be deemed “forward-looking statements”,
including statements respecting the services to be provided by PanGenomic Health and the
consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar
expressions are intended to identify forward looking statements. Although PanGenomic Health
believes that the expectations and assumptions on which the forward-looking statements are
based are reasonable, undue reliance should not be placed on the forward-looking statements
because PanGenomic Health can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by their very nature they involve
inherent risks and uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently anticipated due to a number of
factors and risks including various risk factors discussed in PanGenomic Health’s disclosure
documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information
contained herein and does not accept responsibility for the adequacy or accuracy of this
news release.
